Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000935836-25-000513
Filing Date
2025-08-14
Accepted
2025-08-14 12:38:56
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 11135
2 AGREEMENT berylex991.htm EX-99 9770
  Complete submission text file 0000935836-25-000513.txt   22700
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Subject) CIK: 0001693011 (see all company filings)

EIN.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91586 | Film No.: 251216479
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 225 AVENUE I STE 205 REDONDO BEACH CA 90277
Business Address 225 AVENUE I STE 205 REDONDO BEACH CA 90277 9174461561
Beryl Capital Management LLC (Filed by) CIK: 0001719307 (see all company filings)

EIN.: 474641111 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A